Stock Scorecard
Stock Summary for Bioventus Inc - Class A (BVS) - $7.78 as of 2/2/2026 7:24:57 AM EST
Total Score
8 out of 30
Safety Score
19 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BVS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BVS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BVS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for BVS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for BVS (19 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 2 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Financial Details for BVS
Company Overview |
|
|---|---|
| Ticker | BVS |
| Company Name | Bioventus Inc - Class A |
| Country | N/A |
| Description | Bioventus Inc. (BVS) is a leading medical device company headquartered in Durham, North Carolina, focused on revolutionizing orthopedic care via innovative technologies designed to enhance the body's natural healing processes. The company offers a comprehensive range of products that address pain management and recovery specifically in the musculoskeletal area, aiming to improve patient outcomes globally. With a strong emphasis on advancing patient care through cutting-edge solutions, Bioventus presents valuable growth opportunities for institutional investors looking to capitalize on trends in the evolving health technology landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL DEVICES |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/10/2026 |
Stock Price History |
|
| Last Day Price | 7.78 |
| Price 4 Years Ago | 2.61 |
| Last Day Price Updated | 2/2/2026 7:24:57 AM EST |
| Last Day Volume | 189,689 |
| Average Daily Volume | 241,832 |
| 52-Week High | 11.25 |
| 52-Week Low | 5.81 |
| Last Price to 52 Week Low | 33.91% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 54.83 |
| Sector PE | 188.49 |
| 5-Year Average PE | 15.91 |
| Free Cash Flow Ratio | 12.35 |
| Industry Free Cash Flow Ratio | 19.78 |
| Sector Free Cash Flow Ratio | 30.14 |
| Current Ratio Most Recent Quarter | 1.74 |
| Total Cash Per Share | 0.63 |
| Book Value Per Share Most Recent Quarter | 2.48 |
| Price to Book Ratio | 3.23 |
| Industry Price to Book Ratio | 3.56 |
| Sector Price to Book Ratio | 57.14 |
| Price to Sales Ratio Twelve Trailing Months | 0.95 |
| Industry Price to Sales Ratio Twelve Trailing Months | 6.56 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.56 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 66,976,000 |
| Market Capitalization | 521,073,280 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 78.53% |
| Reported EPS 12 Trailing Months | 0.16 |
| Reported EPS Past Year | 0.32 |
| Reported EPS Prior Year | 0.47 |
| Net Income Twelve Trailing Months | 7,821,000 |
| Net Income Past Year | -33,542,000 |
| Net Income Prior Year | -156,230,000 |
| Quarterly Revenue Growth YOY | -0.20% |
| 5-Year Revenue Growth | 11.00% |
| Operating Margin Twelve Trailing Months | 8.13% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 42,164,000 |
| Total Cash Past Year | 41,582,000 |
| Total Cash Prior Year | 36,964,000 |
| Net Cash Position Most Recent Quarter | -269,170,000 |
| Net Cash Position Past Year | -266,706,000 |
| Long Term Debt Past Year | 308,288,000 |
| Long Term Debt Prior Year | 366,998,000 |
| Total Debt Most Recent Quarter | 311,334,000 |
| Equity to Debt Ratio Past Year | 0.32 |
| Equity to Debt Ratio Most Recent Quarter | 0.35 |
| Total Stockholder Equity Past Year | 147,940,000 |
| Total Stockholder Equity Prior Year | 173,591,000 |
| Total Stockholder Equity Most Recent Quarter | 166,096,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 53,471,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 0.80 |
| Free Cash Flow Past Year | 37,789,000 |
| Free Cash Flow Prior Year | 7,982,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.11 |
| MACD Signal | 0.12 |
| 20-Day Bollinger Lower Band | 6.34 |
| 20-Day Bollinger Middle Band | 7.28 |
| 20-Day Bollinger Upper Band | 8.21 |
| Beta | 0.79 |
| RSI | 50.37 |
| 50-Day SMA | 7.48 |
| 150-Day SMA | 6.43 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 1/30/2026 7:15:18 PM EST |